Enliven Therapeutics, Inc. (ELVN) Key Metrics
ELVN valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $2.73B
- Enterprise value
- $2.48B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.8 10-yr median 2.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.34
ELVN key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsELVN valuation Price multiples at each fiscal year-end price.
ELVN returns How much profit the business earns on the capital it uses.
ELVN per-share figures Results divided by the shares outstanding at year-end.
ELVN financial health Debt, liquidity and how easily interest is covered.
ELVN efficiency & capital use Working capital cycle and where the cash goes.
ELVN valuation history
ELVN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ELVN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ELVN cash returned to shareholders
ELVN price vs earnings per share
ELVN key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $872.6M | $1.06B | $492.0M | — | — | — | — | — |
| Enterprise value | $410.4M | $745.7M | $239.1M | — | — | — | — | — |
| Price / book | 1.9 | 3.4 | 2.0 | — | — | — | — | — |
| Earnings yield | −11.9% | −8.4% | −14.6% | — | — | — | — | — |
| Free cash flow yield | −8.1% | −6.9% | −12.5% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $15.40 | $22.50 | $13.84 | $16.36 | $9.00 | $88.20 | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Earnings per share | −$1.83 | −$1.89 | −$2.01 | — | — | — | — | — |
| Operating cash flow per share | −$1.24 | −$1.55 | −$1.72 | — | — | — | — | — |
| Free cash flow per share | −$1.24 | −$1.56 | −$1.73 | — | — | — | — | — |
| Cash per share | $8.16 | $6.66 | $7.12 | — | — | — | — | — |
| Book value per share | $8.11 | $6.58 | $6.92 | — | — | — | — | — |
| Tangible book value per share | $8.11 | $6.58 | $6.92 | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Debt per share | $0.01 | — | $0.01 | — | — | — | — | — |
| Shares outstanding | 56.7M | 47.1M | 35.5M | — | — | — | — | — |
| Change in shares outstanding | +20.4% | +32.4% | — | — | — | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −27.0% | −32.0% | −84.7% | — | −25.9% | −106.6% | — | — |
| Return on assets (ROA) | −25.9% | −29.8% | −40.3% | −38.3% | −24.2% | −30.6% | −114.4% | −147.1% |
| Return on tangible assets | −21.8% | −27.3% | −26.3% | −45.2% | −21.8% | −20.9% | −70.5% | −147.1% |
| Financial health | ||||||||
| Total debt | $399,000 | — | $335,000 | $323,000 | $159,000 | $105,000 | — | — |
| Cash & short-term investments | $462.6M | $313.4M | $253.1M | $75.5M | $110.0M | $88.2M | $28.9M | $7.4M |
| Net debt | −$462.2M | −$313.4M | −$252.8M | −$75.2M | −$109.9M | −$88.1M | −$28.9M | −$7.4M |
| Debt / equity | 0.00 | — | 0.00 | — | 0.00 | 0.00 | — | — |
| Debt / assets | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Current ratio | 28.66 | 19.99 | 10.28 | 8.00 | 19.24 | 14.47 | 7.29 | 4.21 |
| Quick ratio | 28.66 | 19.99 | 10.28 | 8.00 | 19.24 | 14.47 | 7.29 | 4.21 |
| Interest coverage | — | — | — | -31.9 | -266.3 | — | — | — |
| Working capital | $458.3M | $302.2M | $240.3M | $68.0M | $104.9M | $84.2M | $26.4M | $5.9M |
| Invested capital | −$2.6M | −$3.6M | −$6.9M | −$152.0M | −$3.0M | −$3.7M | −$77.8M | −$33.7M |
| Tangible asset value | $459.5M | $309.8M | $245.9M | −$76.8M | $106.9M | $84.4M | $28.9M | $5.9M |
| Net current asset value | $458.2M | $302.2M | $240.2M | −$82.4M | $104.2M | $84.0M | $26.2M | $5.9M |
| Graham net-net per share | $7.87 | $6.32 | $6.39 | — | — | — | — | — |
| Capital allocation | ||||||||
| Share buybacks (net) | $0 | — | — | $0 | $226,000 | — | — | — |
| Capex / depreciation | 0.60 | 0.14 | 0.50 | 2.85 | 1.66 | 10.24 | 4.24 | — |
| Efficiency | ||||||||
| Days payables outstanding | 2,429.4 | 1,078.9 | 2,439.5 | 1,748.4 | 8,280.7 | 6,827.8 | 14,190.8 | — |
| Payables turnover | 0.15 | 0.34 | 0.15 | 0.21 | 0.04 | 0.05 | 0.03 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $1.8M | $937,000 | $2.0M | $3.0M | $2.2M | $1.8M | $1.3M | $908,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ELVN's annual financial statements (latest annual report filed March 3, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ELVN valuation and financial ratios
Enliven Therapeutics earned a return on equity of −27.0% in fiscal 2025. It ended the year with $0.4 million of debt and $462.6 million in cash and short-term investments, a net cash position of $462.2 million.
See the ELVN income statement, the ELVN chart for price history, or the ELVN stock overview for the latest quote and news.
ELVN key metrics FAQ
What is Enliven Therapeutics's return on equity?
Enliven Therapeutics's return on equity (ROE) was −27.0% in fiscal 2025: net income of -$103.7 million on average shareholders' equity of $384.7 million.
How much debt does Enliven Therapeutics have?
Enliven Therapeutics had total debt of $0.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Enliven Therapeutics's free cash flow yield?
Enliven Therapeutics generated -$70.5 million of free cash flow in fiscal 2025, a free cash flow yield of −8.1% on its market value at year-end ($872.6 million).
What is Enliven Therapeutics's current ratio?
Enliven Therapeutics's current ratio was 28.66 at the end of fiscal 2025: current assets were 28.66 times current liabilities.